Royce & Associates Cuts Stake in Bio-Techne Corp

Hedge fund reduces holding in biotechnology company by 24.2% in Q3

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Royce & Associates LP, a hedge fund, reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 24.2% during the third quarter, according to a recent SEC filing. The firm previously owned 660,034 shares of the biotechnology company's stock, valued at $36.7 million, but sold 210,853 shares during the period.

Why it matters

Bio-Techne is a major player in the biotechnology industry, providing reagents, instruments, and services to researchers and clinicians. Changes in institutional ownership of the company's stock can signal shifts in investor sentiment and potentially impact the stock price.

The details

According to the 13F filing, Royce & Associates now owns 0.42% of Bio-Techne's outstanding shares. The hedge fund cited unspecified reasons for reducing its position in the company. Bio-Techne's stock has seen volatility in recent months, with the share price ranging from $46.01 to $72.16 over the past 52 weeks.

  • Royce & Associates filed its 13F for the third quarter of 2026 on March 2, 2026.
  • The filing shows the hedge fund's holdings as of the end of the third quarter, which was September 30, 2026.

The players

Royce & Associates LP

A hedge fund that previously owned a 0.42% stake in Bio-Techne Corp.

Bio-Techne Corp

A biotechnology company that develops and sells reagents, instruments, and services for research, diagnostic, and bioprocessing markets.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Royce & Associates' stake in Bio-Techne Corp could signal a shift in investor sentiment towards the biotechnology company, though the specific reasons behind the hedge fund's decision are unclear. Investors will likely continue to monitor institutional ownership and stock price movements for Bio-Techne as an indicator of the company's performance and future prospects.